Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Insider Sells $11,738.65 in Stock

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) insider Phil Skolnick sold 385 shares of the business’s stock in a transaction that occurred on Monday, January 10th. The shares were sold at an average price of $30.49, for a total transaction of $11,738.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

OPNT stock opened at $27.07 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 9.23 and a quick ratio of 9.23. Opiant Pharmaceuticals, Inc. has a one year low of $8.51 and a one year high of $37.71. The stock has a market cap of $127.77 million, a PE ratio of 541.51 and a beta of 0.51. The firm has a 50 day simple moving average of $30.12 and a two-hundred day simple moving average of $23.26.

Opiant Pharmaceuticals (NASDAQ:OPNT) last released its quarterly earnings results on Thursday, November 11th. The technology company reported $0.56 EPS for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.41. Opiant Pharmaceuticals had a net margin of 3.58% and a return on equity of 4.25%. The business had revenue of $16.34 million during the quarter, compared to analysts’ expectations of $12.45 million. During the same quarter in the previous year, the company earned $0.15 EPS. On average, research analysts expect that Opiant Pharmaceuticals, Inc. will post 0.39 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in OPNT. Two Sigma Advisers LP purchased a new stake in shares of Opiant Pharmaceuticals in the 3rd quarter valued at $2,139,000. EAM Investors LLC purchased a new stake in shares of Opiant Pharmaceuticals in the 3rd quarter valued at $1,777,000. Two Sigma Investments LP purchased a new stake in shares of Opiant Pharmaceuticals in the 3rd quarter valued at $1,314,000. Geode Capital Management LLC boosted its stake in shares of Opiant Pharmaceuticals by 290.0% in the 3rd quarter. Geode Capital Management LLC now owns 50,244 shares of the technology company’s stock valued at $1,293,000 after purchasing an additional 37,362 shares in the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new stake in shares of Opiant Pharmaceuticals in the 3rd quarter valued at $772,000. 26.90% of the stock is owned by institutional investors.

Separately, Oppenheimer began coverage on shares of Opiant Pharmaceuticals in a research note on Wednesday, December 8th. They set an “outperform” rating and a $42.00 price objective for the company.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa.

Further Reading: Stock Market – What is a circuit breaker?

Insider Buying and Selling by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.